163 related articles for article (PubMed ID: 3956142)
1. Six-year retrospective survey of the resistance of Bacteroides fragilis group species to clindamycin and cefoxitin.
Wexler HM; Harris B; Carter WT; Finegold SM
Diagn Microbiol Infect Dis; 1986 Mar; 4(3):247-53. PubMed ID: 3956142
[TBL] [Abstract][Full Text] [Related]
2. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
Goldstein EJ; Citron DM
J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.
Turgeon P; Turgeon V; Gourdeau M; Dubois J; Lamothe F
Antimicrob Agents Chemother; 1994 Oct; 38(10):2276-9. PubMed ID: 7840557
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
Stratton CW; Weeks LS; Aldridge KE
Diagn Microbiol Infect Dis; 1991; 14(5):377-82. PubMed ID: 1797454
[TBL] [Abstract][Full Text] [Related]
5. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.
Teng LJ; Hsueh PR; Tsai JC; Liaw SJ; Ho SW; Luh KT
Antimicrob Agents Chemother; 2002 Sep; 46(9):2908-13. PubMed ID: 12183246
[TBL] [Abstract][Full Text] [Related]
6. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
[TBL] [Abstract][Full Text] [Related]
7. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.
Aldridge KE; Ashcraft D; Cambre K; Pierson CL; Jenkins SG; Rosenblatt JE
Antimicrob Agents Chemother; 2001 Apr; 45(4):1238-43. PubMed ID: 11257040
[TBL] [Abstract][Full Text] [Related]
8. The antibiotic sensitivity of the Bacteroides fragilis group in the United Kingdom.
Fox AR; Phillips I
J Antimicrob Chemother; 1987 Oct; 20(4):477-88. PubMed ID: 3680088
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
[TBL] [Abstract][Full Text] [Related]
10. Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates.
Bieluch VM; Cuchural GJ; Snydman DR; Gorbach SL; Tally FP
Diagn Microbiol Infect Dis; 1987 Jun; 7(2):119-26. PubMed ID: 3652652
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of flomoxef compared to moxalactam, cefoxitin, cefotaxime, and clindamycin against anaerobes.
Werner H; Heizmann W; Luft G
Arzneimittelforschung; 1988 Nov; 38(11):1553-6. PubMed ID: 3214438
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of cefoxitin, cefotaxime alone, and in combination with desacetylcefotaxime against the Bacteroides species.
Canawati HN
Diagn Microbiol Infect Dis; 1989; 12(1):33-7. PubMed ID: 2714070
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of clindamycin resistance in the Bacteroides fragilis group.
Reig M; Campello MG; Baquero F
J Antimicrob Chemother; 1984 Dec; 14(6):595-603. PubMed ID: 6520060
[TBL] [Abstract][Full Text] [Related]
14. Bacteroides fragilis resistant to metronidazole, clindamycin and cefoxitin.
Brogan O; Garnett PA; Brown R
J Antimicrob Chemother; 1989 Apr; 23(4):660-2. PubMed ID: 2745269
[No Abstract] [Full Text] [Related]
15. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Golan Y; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Yu V; Rihs J; Gorbach SL
Antimicrob Agents Chemother; 2007 May; 51(5):1649-55. PubMed ID: 17283189
[TBL] [Abstract][Full Text] [Related]
16. Variations in susceptibility to latamoxef(moxalactam) and cefoxitin within the Bacteroides fragilis group.
Eley A; Greenwood D
J Antimicrob Chemother; 1984 Mar; 13(3):245-55. PubMed ID: 6725175
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study.
Karlowsky JA; Walkty AJ; Adam HJ; Baxter MR; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2012 Mar; 56(3):1247-52. PubMed ID: 22203594
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
Stratton CW; Weeks LS; Aldridge KE
Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and susceptibility of resistant Bacteroides fragilis group organisms to new beta-lactam antibiotics.
Heseltine PN; Appleman MD; Leedom JM
Rev Infect Dis; 1984; 6 Suppl 1():S254-9. PubMed ID: 6585882
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology, antimicrobial susceptibility, pathogenicity, and significance of Bacteroides fragilis group organisms isolated at Los Angeles County-University of Southern California Medical Center.
Appleman MD; Heseltine PN; Cherubin CE
Rev Infect Dis; 1991; 13(1):12-8. PubMed ID: 2017610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
